|
|
MASCC/ISOO 18th International Symposium
June 22 - June 24, 2006 - Toronto, Canada
2006 Symposium Award Recipients 2006 Distinguished Service Award
Richard Gralla
 | | Paul Hesketh, President, presented the MASCC Distinguished Service to Richard Gralla, MD at the opening ceremonies of the 18th International Symposium, Supportive Care in Cancer, in Toronto Canada on June 22, 2006. Dr. Hesketh noted that this award is the highest honor MASCC can bestow. It acknowledges an individual who has made extraordinary contributions to the Society. Here are Dr. Hesketh’s remarks as he presented the award:
“Dr. Gralla has been with MASCC from its inception. Without his innumerable efforts over the years, MASCC would not be in its current |
preeminent leadership position within the supportive care arena. Dr. Gralla served for a number of years as a vice-president of the society, has been an important contributor to the success of our journal serving as an Associate Editor and chaired the 1994 MASCC meeting in New Orleans. In 2000, he became the second president of MASCC succeeding Jean Klastersky. He clearly had a very tough act to follow given the pioneering leadership and vision displayed by his predecessor Professor Klastersky. He served as president until 2004. One of his first initiatives was to begin for the first time in the society’s history a comprehensive strategic planning process. Under his leadership MASCC was transformed from an organization totally dependent on uncompensated volunteers to a modern society with a professional infrastructure composed of a number of very talented and devoted staff members. The financial stability of the society was dramatically improved providing an ability to plan and execute a number of new initiatives. Over the past 2 years, Dr. Gralla has continued to play a key leadership role in our society as the immediate past president and a member of the executive committee. We are extraordinarily grateful to Dr. Gralla for all that he has done for MASCC and look forward to his continued active involvement in our society.â€
2006 Outstanding Young Investigator's Award
Joanne Bowen, BHSc – Australia
Supported by: Merck & Co., Inc.
 | Joanne is a new investigator having completed her studies in February 2006 with a PhD in Medicine from The University of Adelaide. The focus of her research has been the molecular control of chemotherapy-induced mucositis and the work detailed in this thesis has since been published or submitted for publication in a series of four manuscripts. During her candidature she has also published widely, relative to opportunity, with over twenty three abstracts at local, national and international scientific meetings, as well as ten publications in international journals with a further three manuscripts submitted. Joanne’s research has |
detailed for the first time the similarities in genetic responses to anti-cancer treatment along the gastrointestinal tract regardless of inducing agent or species. These findings have led her to continued research through the appointment as a Royal Adelaide Hospital Research Associate. Ms Bowen has been successful in obtaining a Cancer Council South Australia Travel Grant in 2005 and 2006 to travel MASCC. She has also been invited to travel to Boston to visit the laboratory of Professor Steve Sonis, an internationally recognised expert in oral mucositis. Joanne is a current member of MASCC/ISOO and an active member of the Mucositis Study Group, contributing to the Guidelines update in 2005. She is also a senior member of the Mucositis Research Group based at the Royal Adelaide Hospital, Department of Medial Oncology. She has also been active in supervising students in the Mucositis Research Group and has successfully mentored 3rd year Biomedical Science students from The University of Adelaide during the past two years. Joanne is aiming to continue cutting-edge research in mucositis through appointment to future postdoctoral positions.
| Young Investigator Awards |
Supported by: Merck & Co., Inc.
Joanne Bowen, BHSc – Australia
Christopher Booth, MD – Canada
Katherine Hauser, MD – United States
Pascal Jean-Pierre, PhD – United States
Nicole Kuderer, MD – United States
Anya Murphy, MD – Ireland
Andrea Stringer – Australia
Sukirtha Tharmalingam – Canada
Thuan Tran, MD – Vietnam
Janette Vardy - Canada
| Travel Scholarship Recipients |
Supported by: Serenex, Inc. Merck & Co., Inc., and MGI Pharma, Inc.
Natalia Carafizi, MD – Moldova
Monica Castro, MD – Argentina
Aline Lauda Chaves Freitas, MD – Brazil
Camelia-Aneta Colichi, MD – Romania
Pimkhuan Kamnerdsupaphon, MD – Thailand
Vladyslav Myhalskyy, MD – Ukraine
Alfredo Navigante, MD – Argentina
Maxim Petrov, MD – Turkey
Oxana Pihut, MD - Moldova
Janice Kagendo Riungu, RN – Kenya
Vijay Roy, M Pharm – India
Paulo Sérgio d Silva Santos, DDS – Brazil
Jolanta Toliusiene, RN – Lithuania
Stefanel Cornel Vlad, MD - Romania
| Highlighted Abstract Awards |
 View the 18th MASCC/ISOO Symposium Abstracts(PDF-900K)
Eltrombopag, An Oral Platelet Growth Factor, Increases Platelet Counts During 6-Week Treatment Of Subjects With ITP – Results Of A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
James Bussel1, Gregory Chen2, Mansoor Saleh3, Lidia Kovaleva4, Nicole Stone5, Andrew Provan6
Do Pain, Depression And Fatigue Cluster In Advanced Cancer?
Declan Walsh, Lisa Rybicki, Katherine Hauser
Cognitive Impairment Associated With Chemotherapy For Breast Cancer: An Exploratory Case-Control Study.
Christopher Booth1, Janette Vardy1, Adrian Crawley2, Sean Rourke3, Lynne Wagner4, Ian Tannock1
In a Randomized Phase II Trial Casopitant Mesylate + Ondansetron and Dexamethasone Reduced Chemotherapy-Induced Nausea/Vomiting (CINV) in Patients Receiving Moderately Emetogenic Chemotherapy (MEC).
Wichit Arpornwirat1, Istvan Albert2, Vincent Hansen3, Julian Jenkins4, Rajesh Bandekar4, Steven Grunberg5
In a Randomized Phase II Trial, Casopitant Mesylate+Ondansetron and Dexamethasone Reduced Chemotherapy-Induced Nausea/Vomiting (CINV) in Cancer Patients Receiving Highly Emetogenic Chemotherapy (HEC).
Janusz Rolski1, Rodryg Ramlau2, Mircea Dediu3, Julian Jenkins4, Rajesh Bandekar4, Steven Grunberg5
Identifying Patients at High Risk for Moderate to Severe Nausea and Vomiting Following Chemotherapy: The Development and Validation of a Prediction Tool for the Practicing Oncologist.
Teresa Petrella1, Anil Joy2, Scott Young3, Walter Callaghan1, Mark Clemons1, Maureen Trudeau1, George Dranitsaris1
|
|
QuickLinks
Virtual Meeting
Journal Reviews
|
